Today: 9 April 2026
Subscribe
Browse Category

Biotechnology 5 January 2026 - 9 January 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology shares surged 25.1% to $52.45 after the company advanced the expected release of late-stage bladder cancer trial results to the first half of 2026. The PIVOT-006 Phase 3 trial enrolled over 360 patients and compares cretostimogene grenadenorepvec to surveillance after tumor removal. Trading volume topped 4.1 million shares by midday. Morgan Stanley raised its price target on the stock to $89.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering shares surged 24% to $8.33 premarket after reporting 64% overall 12-month survival in a 34-patient Phase 2a pancreatic cancer trial. The company compared this to a 35% benchmark from standard chemotherapy. Median progression-free survival reached 8.5 months. Immuneering plans a larger data update and to start a Phase 3 trial in mid-2026.
8 January 2026
···
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
···
Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics shares rose 5.6% to $66.75 after an SEC filing revealed a $100 million upfront payment and low single-digit royalties from Roche and Genentech for a patent license covering oral GLP-1 drugs, including CT-996. The agreement does not affect Structure’s lead candidate, aleniglipron. Full contract details will be disclosed in the annual report.
7 January 2026
·
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience Holdings shares jumped 18.3% to $31.99 in midday Nasdaq trading Tuesday, after swinging between $26.60 and $34.40. No new company statements have been posted since its Oct. 31 annual report, which disclosed a DOJ trading probe and “substantial doubt” about its ability to continue as a going concern. About 850,000 shares changed hands.
6 January 2026
··
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences shares surged 17.2% to $17.58 Tuesday on heavy volume, after new data from Arrowhead Pharmaceuticals showed weight loss benefits from RNAi obesity drugs. Wave is developing a similar therapy, WVE-007, targeting the same gene. The company recently raised $402.5 million in a public offering. Investors await further trial results expected in early 2026.
6 January 2026
··
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics shares surged 46% to $2.01 premarket Tuesday after announcing an expanded exclusive collaboration with Medsteer for its CYC-126 depression program. The company aims to start a Phase 2 proof-of-concept study in late 2026, with initial data expected in 2027. Cyclerion flagged “substantial doubt” about its ability to continue as a going concern and said it needs more funding.
6 January 2026
··
Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific shares climbed 2.4% to $606.63 after Evercore ISI raised its price target to $650 and reaffirmed an “outperform” rating. The stock traded between $590 and $608.29 on volume of 1.6 million shares. Peers Danaher, Agilent, and Illumina also advanced. Investors await Thermo Fisher’s fourth-quarter results on Jan. 29 and updates on its planned $9.4 billion Clario acquisition.
5 January 2026
···
1 … 3 4 5 6 7 … 16

Stock Market Today

  • Wix.com (WIX) Faces Steep Share Price Decline, Valuation Close to Fair Value
    April 8, 2026, 6:30 PM EDT. Wix.com (WIX) stock has fallen sharply over multiple time frames, down 54.9% in one year and 74.3% in five years, reflecting significant market pressure. The stock recently closed at $74.40, showing a 17.8% drop in the past week. Despite this drop, a Discounted Cash Flow (DCF) model estimates Wix.com's intrinsic value at $69.88 per share, suggesting the current price trades about 6.5% above fair value. This implies investors may have factored in recent challenges, even as the company maintains positive cash flow projections. Wix.com's high price-to-earnings (P/E) ratio of 85.67 indicates strong growth expectations but also elevated risk. Investors should monitor valuation shifts amid ongoing volatility and changing market sentiment.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop